<DOC>
	<DOC>NCT00602550</DOC>
	<brief_summary>The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's RetrovirÂ® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of Zidovudine Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening. Allergic or adverse responses to zidovudine or any other comparable or similar products. Participation in clinical trial within 30 days of study initiation. Positive blood screen for HIV, Hepatitis B and C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>HIV</keyword>
</DOC>